Artemisinins are effective against a variety of parasites and provide the first line of treatment for malaria. Laboratory studies have identified several mechanisms for artemisinin resistance in Plasmodium falciparum, including mutations in Kelch13 that are associated with delayed clearance in some clinical isolates, although other mechanisms are likely involved. To explore other potential mechanisms of resistance in parasites, we took advantage of the genetic tractability of T. gondii, a related apicomplexan parasite that shows moderate sensitivity to artemisinin. Resistant populations of T. gondii were selected by culture in increasing drug concentrations and whole genome sequencing identified several non-conservative point mutations that emerged in the population and were fixed over time. Genome editing using CRISPR/Cas9 was used to introduce point mutations conferring amino acids changes in a serine protease homologous to DegP and a serine/threonine protein kinase of unknown function. Single and double mutations conferred a competitive advantage over wild type parasites in the presence of drug, despite not changing EC 50 values. Additionally, the evolved resistant lines showed dramatic amplification of the mitochondrial genome, including genes encoding cytochrome b and cytochrome oxidase I. Consistent with prior studies in yeast and mammalian tumor cells that implicate the mitochondrion as a target of artemisinins, treatment of wild type parasites with artemisinin decreased mitochondrial membrane potential, and resistant parasites showed altered morphology and decreased membrane potential. These findings extend the repertoire of mutations associated with artemisinin resistance and suggest that the mitochondrion may be an important target of inhibition in T. gondii.
Introduction
Toxoplasma gondii is a widespread parasite of animals that also frequently causes zoonotic infections in people (1). Serological testing suggests that ~1/3 of the global human population is chronically infected (2), although such infections are typically well controlled by the immune response following mild clinical symptoms in the acute phase (3). Chronic infections are characterized by semi-dormant tissue cysts containing bradyzoites, which divide asynchronously and sporadically (4). Current therapies and induction of a potent immune response are insufficient to clear these stages and instead they undergo slow turnover to sustain infection over time. Re-emergence of chronic infection in patients that are immunocompromised results in serious disease (5, 6) , especially when this occurs in the central nervous system where tissue cysts most often infect neurons (7) . Toxoplasmosis is also a threat due to risk of congenital infection, especially in resource-limited regions (8). More severe disease has been reported in some regions of South America where infections are associated with ocular disease in otherwise healthy individuals (9). Toxoplasmosis is typically treated by anti-folates using a combination of pyrimethamine -sulfadiazine or trimethoprim-sulfamethoxazole, although pyrimethamine has also been used in combination with clindamycin, azithromycin, and atovaquone (also used as monotherapy) (10). With the exception of congenital infection, infections are not commonly transferred from human-to-human, so emergence of drug resistance is rarely a problem.
However, several examples of clinical failure have been reported in patients given atovaquone as a monotherapy (11, 12) .
Combination therapies including artemisinin (ART) are the first line of treatment against malaria (13). Since their original discovery (14), a wide variety of analogs have been made to improve solubility and other drug-like properties, including artemether, artusunate and dihydroartemisinin, which is the active form in vivo (15) . ART therapies are fast acting and effective across multiple life cycle stages; however, they have short half lives in vivo and must be coupled with longer lasting partner drugs to reduce the risk of resistance development (13) . ART derivatives share an endoperoxide bond that is essential for activity, demonstrated by the fact that the derivative deoxyartemisinin loses antimalarial activity (16). More recently, completely synthetic analogs containing a similar ozonide group have been developed and some of these have increased half lives in vivo (17) . ART analogs are also effective in blocking growth of T. gondii in vitro (18) (19) (20) and controlling infection in vivo in murine models of toxoplasmosis (21, 22) . Although analogs show similar potency ranking, they are effective against T. gondii at ~50-fold higher concentrations when compared to P. falciparum (20, 23) . This major difference in sensitivity may be due to the fact that P. falciparum digests hemoglobin in the food vacuole and releases heme in high concentrations (24) . The majority of heme is detoxified into a crystalline form called hemozoin, and yet it is likely that elevated reduced iron (Fe 2+ ) is present in the food vacuole.
One potential mechanism is that free Fe 2+ activates the endoperoxide bond (25), resulting in formation of adducts to a variety of protein and lipid targets that result in parasite death (26, 27) . There is no analogous process to hemoglobin digestion in T. gondii, which may explain its lower sensitivity to ART.
Instead, it is possible that heme derived from sources such as mitochondria plays an important role in activating ART in T. gondii, similar to yeast and tumor cell models, as discussed below.
Treatment failure in P. falciparum patients treated with ART was first reported in western Cambodia as a delayed clearance phenotype (28) . However, such isolates are not "resistant" by the classical definition of shifted EC 50 ; rather they show delayed clearance times compared to the normal rapid drop in parasitemia following ART treatment (13) . The delayed clearance phenotype from many SE Asian isolates correlates with outgrowth after high dose treatment of ring stages in vitro, the basis for the Ring stage Survival Assay (RSA) (29) . Selection for ART-resistant P. falciparum lines in the laboratory by step-wise increases in drug concentration led to identification of mutations in a Kelch13 (K13) ortholog (30) . Subsequent reverse genetic experiments confirmed that these mutations were capable of conferring resistance in a wild type background (31) . Additionally, a number of K13 mutations were found in high abundance in SE Asia where they correlated with RSA sensitivity (30).
Several mechanisms have been proposed to explain the role of K13 in ART resistance, including an enhanced cell stress response leading to upregulation of the unfolded protein response, decreased ubiquitination, and increased cell survival (32) . Consistent with this model, inhibitors of the proteasome synergize with artemisinin (33, 34) . However, other studies have reported the development of delayed clearance or dormancy phenotypes in P. falciparum-infected patients without associated K13 mutations (35, 36) . Furthermore, genetic crosses between parasite lines bearing sensitive vs. resistant K13 mutations demonstrated a correlation with the RSA assay in vitro but not with clearance of blood infection following treatment of infected Aotus monkeys, suggesting other mechanisms are responsible in vivo (37) . Separately it has been proposed that ART inhibits PI 3 K, and that K13 mutations that confer resistance led to increased PI 3 K activity and increased IP 3 and membrane vesicles that may confer protection to ring stages (38) . In a separate study involving in vitro selections, resistanceconferring mutations were identified in a number of genes including the actin-binding protein coronin(39). In summary, there are a number of distinct mechanisms that can lead to decreased sensitivity of P. falciparum to ART, which complicates efforts to track the development of resistance in the field.
A number of specialized artemisinin derivatives have been synthesized and promoted as potential treatments for cancer as they are active against a wide variety of tumor cells in vitro (40) . The activities of the common ART derivatives against tumor cell lines are in the low micromolar range, which is comparable to their activity in T. gondii but much higher than what is typically observed against insensitivity as the mitochondria is dispensable under these conditions (43) . Treatment of yeast with ART results in mitochondrial membrane depolarization, suggesting that ART is activated by the electron transport system which leads to oxidative stress and membrane damage (44) . Inhibition of mitochondrial function in tumor cells treated with ART derivatives has also been shown to promote cell death due to apoptosis (45) . In human tumor cells, it is proposed that mitochondrial heme activates the endoperoxide group of artemisinin and interaction with the electron transport chain generates reactive oxygen species leading to cell death (46) .
Here we used the versatility of T. gondii as a genetic system to explore potential mechanisms of resistance to ART. Toxoplasma can be propagated asexually for long periods of time and single cell clones can be readily isolated, cryopreserved, and expanded. Multiple high-quality genome assemblies of the haploid ~ 65 Mb genome are available from a diverse set of strains (47) and efficient systems are available for reverse genetics using CRIPSR/Cas9 (48) . Previous studies have shown that ART resistance can be selected in chemically-mutagenized T. gondii parasites (49), although the molecular mechanism for the modest shift in EC 50 observed in these resistant clones was not defined. Chemical mutation introduces numerous changes in the genome, confounding analysis of those that might confer resistance. Consequently, we used a natural evolution process to select for mutations that would confer increased survival in ART, while monitoring the background mutation rate in the absence of selection in parallel. We applied selective pressure by growing parasites for many generations in increasing concentrations of ART and were able to obtain resistant populations as evidenced by increased EC 50 values. Whole genome sequencing identified several single nucleotide polymorphisms that arose in the resistant populations and reached fixation over time. Reverse genetic approaches based on CRISPR/Cas9 gene editing were used to show that these mutations confer increased competitive advantage over wildtype, consistent with enhanced tolerance, despite the fact that they did not alter EC 50 values. Additionally, the resistant populations showed stable changes in the mitochondrion, which may contribute to resistance. These findings define novel molecular changes associated with ART resistance in T. gondii, which may be informative for understanding the mechanism of action of this important class of compounds.
Results

Estimating the background mutation rate in T. gondii.
Prior to selecting for resistant parasites, we wanted to establish the background mutation rate of T.
gondii during a continuous in vitro passage under standard laboratory conditions. Because lines that have been cultured for years in the laboratory are likely a mixture of genotypes that contain both private and shared single nucleotide polymorphisms (SNPs), as well as potential copy number variations (CNVs), we first cloned the starting population by limiting dilution on monolayers of human foreskin fibroblasts (HFF cells). We obtained clones from the common laboratory RH strain, referred to herein as the 5D and 12B lines, and grew them by sequential passage in HFF cells for 365 days, sub-culturing them every 2-3 days ( Fig. 1A) . During in vitro passage in this format, the total population parasite size of a given culture expands to ~ 2x10 7 over a time frame of 2-3 days. The population is then reduced by 1:10 or 1:20 when a fraction of the growing culture is used to inoculate a new flask of previously uninfected HFF cells. At the time points of 182 and 365 days, separate subclones from the growing populations were isolated by limiting dilution, and these were named with the prefix of the parental line followed by a clone designation ( Fig. 1A) . Genomic DNA extracted from these clones and their respective parents were whole genome sequenced using Illumina technology. The short reads were mapped with high stringency to the reference genome of the ME49 strain of T. gondii (www.ToxoDB.org) using a specially developed pipeline (see methods). We then identified and compared SNP frequencies between the reference parental clones (i.e. 12B and 5D) and the subclones that were obtained from these lines following passage. Overall the number of mutations detected in the clones were quite low with a range from 0 -8 SNPs observed per clone (Datasets S1, S2).
SNP frequency was used to derive approximate rates of mutation based on the assumption that the parasite doubles every ~6 hr (four generations per day) (50) and that the composite genome is roughly 6.5 x 10 6 bp ( 4 7 )
. We calculated the rates for mutation in individual clones with the assumption that the mutants arose spontaneously and that the rates of mutation and growth were constant during the course of the experiment (Datasets S1, S2). Based on these calculations, the average rates over the course of the 365 day culture period were 6.62 x 10 -11 mutations / bp / generation for the 5D clones and 4.71 x 10 -11 mutations / bp / generation for the 12B clones. We also estimated the composite mutation rate for both sets of clones by treating the frequency of SNPs as mutants in a classic fluctuation analysis yielding a combined rate of 5.79 x 10 -11 (Datasets S1, S2). Since both methods give highly similar rates, we used the later value rounded to 5.8 x 10 -11 for subsequent analysis.
When comparing the types of mutations found in each of the lines, we observed approximately equal number of variants occurring in coding and noncoding regions (19 coding vs. 13 noncoding in 5D
and 10 coding vs. 13 noncoding in 12B). However, within coding regions there was a marked increase in nonsynonymous mutations vs. synonymous mutations with a dN/dS ratio of 2.8 for 5D-derived clones and dN/dS ratio of 9 for 12B-derived clones. These high dN/dS ratios suggest strong selective pressure during the culture, although these clones were grown under standard laboratory conditions. In addition, there were some mutations that had apparently reached fixation as they were common to multiple clones from a particular line. For example, in clones from the 12B line, there was a missense mutation in a hypothetical protein that was found in all 6 clones (Dataset S1). Similarly, in clones from line 5D, there were two frameshift mutations in hypothetical proteins, one missense mutation in a hypothetical protein, and one intronic mutation that occurred in multiple clones (Dataset S2).
Establishment of ART-resistant mutants of T. gondii.
Based on the background mutation rate, we designed an experimental protocol using sequential in vitro culture of relatively large parasite populations in combination with stepwise increases in drug concentrations to generate parasites with elevated ART resistance. To initiate this trial, we recloned the 5D line to derive two parental lines designated as B2 and F4 and cultured them in HFF cells supplemented with 8 µM ART as a starting point for selecting parasite populations ( Fig. 1B) . Although growth was initially delayed, as evident from the time required to lyse the host cell monolayer, after 122 days of sequential passage at 8 µM ART, both lineages exhibited reproducible growth and rapidly lead to lysis of the monolayer within 2-3 days of inoculation. At this time point, we cryopreserved each line for future study; these lines are referred to as F4_ART8 and B2_ART8 (Fig. 1B) . We then increased the ART concentration by two-fold to 16 µM and continued to passage both lines with drug until attaining the phenotype of reproducible growth and infectivity, which took approximately 122 days. At this time point, we cryopreserved each line for future study; these lines are referred to as F4_ART16 and B2_ART816 ( Fig. 1B) . We then increased the concentration of ART to 100 µM and passaged the lines for an additional 100 days, after which they showed normal growth. At this stage, we generated subclones from each of the F4 and B2 lines gown at 100 µM ART by limiting dilution (Fig. 1B) .
Identification of candidate genes associated with ART resistance.
To determine the extent of resistance that had developed during selection, we tested the 8 µM and 16 µM populations from both the B2 and F4 lines across a dilution series of ART and calculated their EC 50 for growth inhibition. The evolved populations showed a ~3 and ~6 fold increase in EC 50 in the 8 µM and 16 µM resistant populations, respectively (Fig. 1C ). To analyze genetic changes that might have conferred enhanced ART resistance, genomic DNA from all three of the selected populations from both clones (i.e. 8, 16 and 100 µM) was extracted and subjected to whole genome sequencing. Mapping of the reads to the reference genome identified nonsynonymous mutations in the selected populations that were not present in the parental lines. The background rate of mutation is 2-3 fold higher than in non-selected lines and a number of these are found in a majority of clones, albeit typically not in coding regions (Datasets S3, S4). Analysis of the mutation frequency in these clones, including those mutations in DegP or Ark1, gave a rate of 1.39 x 10 -10 for the B2 clones (Dataset S3) and 9.77 x 10 -11 for the F4 clones (Dataset S4). Several of the changes were only detected in one of the two selected lines. For example, mutations were identified in two candidate genes in selected lines derived only from the B2 line and in five candidate genes derived only from the F4 line (SI Appendix, Table S1 ). The majority of these changes were also only found at the highest level of selection (i.e. 100 µM ART), where they were present at allele frequencies of > 90% (SI Appendix, Table S1 ). Because they were not common to both lines, we did not pursue them further, although it remains possible that they contributed to the observed ART resistance phenotypes.
In addition, we detected nonsynonymous changes in two genes that were common to the ART resistant populations derived from both lines. The first of these was in the gene TGME49_290840, which is annotated in ToxoDB as a serine protease (Table 1) . It has high similarity to DegP in P.
malariae (expect value based on BLASTP = 2e-103; XP_028860031.1) and is referred to here as a DegP orthologue. This DegP ortholog is different from a previously named DegP-like serine protease that is localized in the rhoptry of T. gondii (51). We consider TGME49_290840 to be the authentic mitochondrial DegP ortholog based on the presence of a degP-htrA superfamily motif and detection in the mitochondrial proteome (52). The T. gondii DegP orthologue was mutated in a different position in each of the F4 and B2 lines, although both non-conservative mutations resided in the PDZ2 domain (DegP-F4-E821Q and DegP-B2-G806E) ( Table 1 ). The frequencies of the mutated DegP alleles were 50% and 68.08% in F4 and B2 8 µM populations respectively, and these rose to 84% and 98.61% in the 16 µM populations, respectively ( Table 1 ). The second gene identified in both clones was TGME49_239240, which is annotated in ToxoDB as a serine/threonine protein kinase with similarity to calmodulin-dependent and myosin light chain kinases. Because its function is unknown in T. gondii, it is referred to here as artemisinin resistance kinase 1 (Ark1). The mutations in Ark1 occurred at the same site, which resides in the hinge region of the ATP binding pocket, with a different non-conservative substitution in each lineage (Ark1-F4-C274R and Ark1-B2-C274F). Mutations appeared in Ark1 in 70.58% of the reads in the B2 8 µM population but only 4.1% mutant allele reads in the 8 µM population from the F4 line (Table 1) . However, in the 16 µM populations, Ark1 mutated alleles reached 90% and 100% abundance in F4 and B2 populations, respectively ( Table 1 ). The frequency of mutations in both genes increased to 100% in the 100µM ART selected populations from both B2 and F4 lines ( Table 1) .
Validation of the DegP and Ark1 mutations in conferring ART tolerance.
To establish a functional link between the identified mutations and ART resistance, we used a CRISPR/Cas9 based markerless genome editing strategy to introduce non-synonymous SNPs into the endogenous loci of the wild type parental line ( Fig. 2A ) (53). Two pairs of mutations were created to simulate mutations identified in the B2 and F4 resistant lines. Each set consisted of clones with single mutants in DegP, single mutants in Ark1, and double mutants of both DegP and Ark1. Initially, we reconstituted the DegP G806E and Ark1 C274F mutations from the F4 line, either alone or together.
We then constructed similar mutants based on the DegP E821Q and Ark1 C274R mutations from B2.
The point mutations were introduced into a wild type RH ∆ ku80 line expressing firefly luciferase (FLUC), so that we could use a luciferase-based growth assay to monitor growth more precisely. The correct mutations were confirmed by restriction enzyme digestion followed by Sanger sequencing of an amplicon flanking the mutated residue. Surprisingly, introduction of any single-or double-point mutation from either lineage resulted in only a slight increase in EC 50 ranging from 1.2-1.6-fold ( Fig. 2B , 2C)(SI Appendix, Table S2 ) but did not recapitulate their phenotypes shown in Fig. 1C , suggesting that the mutations confer enhanced tolerance to drug. One possible explanation for these results is that additional mutations observed in the original selected populations are required to confer increased ART resistance. However, there were no other mutations found in common between the two lines (SI Appendix, Table S1 ). Additionally, when we analyzed the genomic sequences of B2 and F4 lines grown at 100 µM ART and their respective clones, we also did not detect any additional novel mutations in coding regions that were common to both lineages (SI Appendix, Table S1 , Datasets S3 and S4).
To further characterize the role of these mutations in conferring tolerance to ART, we performed a growth competition assay in vitro under pressure of ART. In these assays an equal number of wild type and mutant parasites were co-cultured in the presence of 16 µM ART or in vehicle DMSO as a control.
When grown in the presence of ART, the mixture of parasites exhibited a slight delay before lysing the monolayer at day 3 vs. the normal day 2 time period. When these parasites were passed onto a fresh HFF monolayer in the presence of ART, they exhibited a growth crash, with variable times of recovery that were dependent on the strains present in culture. Cultures containing DegP mutant parasites were the slowest, with a recovery time of ~11 days. Cultures containing Ark1 mutants exhibited shorter recovery times ranging between 6 and 8 days. The double mutants in both lineages consistently showed the fastest recovery time ranging between 5 to 6 days.
To analyze the proportion of the wild type vs. mutant strains at the initial inoculation and after the recovery from the ART induced growth crash, genomic DNA was extracted at both time points and the respective loci were PCR amplified and analyzed by Sanger sequencing (Fig. 3A) . Remarkably, all single point mutants and their double mutant combinations reproducibly outcompeted the wild type parental strain by the end of the culture period in the presence of ART ( Fig. 3B, 3C ). Of note, while both DegP point mutants showed a fitness defect when co-cultured with the wild type strain under control conditions, they consistently outcompeted the wild type in the presence of ART( Fig. 3B, 3C ).
Interestingly, this growth defect was rescued in the double mutant containing both DegP and Ark1 mutations ( Fig. 3B, 3C ).
T. gondii ART resistant parasites show amplification of the mitochondrial genome.
The resistance to ART in Plasmodium falciparum has been previously shown to be associated with increased pfmdr1 copy-number (54). Hence, we considered the possibility that CNVs within the evolved resistant populations could explain the inability of the single-and double-point mutations to perfectly phenocopy the elevated ART resistance. To examine the genome for CNVs, we mapped the Illumina reads to the whole genome assembly containing the chromosomes of T. gondii and examined the read depth as a proxy for copy number. Our initial assessment of CNVs within the resistant populations uncovered four genes (SI Appendix, Table S3 ) with small regions of elevated read depth in the 100µM artemisinin treated clones (SI Appendix, Fig. S1 ). The amplified regions were quite short, consisting of just 200-300 bps, and all four repeats resided in introns of genes with no known association with drug resistance (SI Appendix, Table S3 ). These regions were also elevated in the parental B2 and F4 lines as compared to the rest of the 1X gene, but the read depth increased dramatically in the 100µM artemisinin treated clones (SI Appendix, Fig. S1 ). Interestingly, all four repeats had top BLAST hits annotated as cytochrome b (COB) or cytochrome c oxidase (COX1), genes that are normally encoded in the mitochondria. The current T. gondii genome assembly does not include the mitochondrial 1 0 derived from COX1 and COB (55). These genes are normally mitochondrially encoded, but many mtDNA fragments have been amplified and transferred to the nuclear genome of T. gondii as scattered imperfect copies that are often flanked by short repeat elements (55). Therefore, we realigned the Illumina reads from the control and the resistant population genomes to the genome assembly, but this time included an independently sequenced portion of the mtDNA spanning COB and COX1 (56) and
unique non-assembled supercontigs that likely also contain reads from the mitochondrial genome. This analysis revealed an amplification of contigs that likely constitute the mtDNA, including genes encoding COX1, COX3, and COB ( Fig. 4, Dataset S5 ). The degree of amplification was very dramatic and proportional to the resistance level of the parasites with the ART 100 μ M populations and clonal genomes showing the highest level of amplification ( Fig. 4 , Dataset S5). Analysis of the mitochondrially encoded genes identified only a few SNPs or short indels in a minority of reads (5-10% overall) without any pattern to ART treatment, indicating that the amplifications are not pseudogenes, truncations, or rearrangements, but rather represent increased copies of the intact genome.
Artemisinin affects T. gondii mitochondrial physiology.
Based on the finding that ART-resistant strains showed amplification of the mitochondrial genome, we investigated the effects of ART treatment on T. gondii mitochondrial biology. First, we assessed mitochondrial membrane potential (ΔΨm) of the ART-resistant and wild type parental parasites upon treatment with the drug. Intracellular wild type parasites were treated for 24 hr with 8 µM ART or vehicle as a negative control ( Fig. 5 ). Because the ART-resistant parasite populations were kept under constant drug pressure over the course of the evolution experiments, we also examined the effect of ART removal for 24 hr (Fig. 5 ). Following the various treatments, cultures were stained with MitoTracker, fixed and further stained for a previously characterized mitochondrial protein TgTom40 with ART did not alter the staining pattern or the intensity of TgTom40 (Fig. 5A ). We then investigated the ART100 resistant population in the presence of 100 µM ART, conditions under which they grow normally. MitoTracker staining revealed a highly atypical pattern consisting of a few bright foci varying in size with a corresponding reduction in fluorescence intensity in other mitochondrial areas that were still readily stained by TgTom40 ( Fig. 5A ). Due to the reduced MitoTracker staining in most regions, there was limited overlap with TgTom40 staining (Fig. 5A ). Culture of the ART100 population for 24 hr in the absence of drug resulted in an increase in MitoTracker signal throughout the parasite mitochondria with the bright foci remaining intact ( Fig. 5A ).
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To quantify the effects of ART treatment on Δ Ψ m, we utilized TMRE (tetramethylrhodamine, ethyl ester) to label active mitochondria. TMRE is a cell permeant, positively charged, red-orange dye that readily accumulates in active mitochondria due to their relative negative charge. Following infection of HFF cells, the monolayers were labeled with TMRE, the parasites were mechanically lysed, and fluorescence levels were read spectrophotometrically in a microtiter plate. Consistent with the observations made with MitoTracker, ART treatment of wild type parasites reduced parasite Δ Ψ m by 60% ( Fig. 5B ). Furthermore, the ART100 population grown in the presence of 100uM ART showed significantly higher Δ Ψ m values compared to those of ART-treated wild type parasites ( Fig. 5B ).
Removal of the drug from the ART100 population exposed to ART for 24 hr lead to a significant increase in Δ Ψ m, although it did not fully return to wild type levels ( Fig 5B) .
We next asked whether the amplification of mitochondrial genome leads to a concomitant increase in nuclear encoded mitochondrial components at both the protein and mRNA levels. To answer this question, protein levels of TgTom40 in wild type and mutant strains were examined by Western blot.
Neither the addition of ART to wild type parasites, nor removal of the drug from the ART100-resistant population led to a change in TgTom40 levels when compared to that of the untreated wild type cells ( Fig. 5C ). Nuclear genes that encode proteins imported into the mitochondrion (i.e. TOM40 and Succinate dehydrogenase [ubiquinone] iron-sulfur subunit succinate dehydrogenase SDHB) showed similar transcript levels in wild type parasites upon addition of ART, and in ART100 populations in the presence or absence of drug ( Fig. 5D ). In contrast, the ART100 population showed significantly higher transcript levels for the mitochondrially encoded COX1 and COB genes compared to wild type parasites ( Fig. 5D ). Transcript levels for these genes were also responsive to ART removal, resulting in a significant drop ( Fig. 5D ) which was consistent with the change in Δ Ψ m in ART100 population grown without the drug Fig. 5B ).
Finally, we characterized ART effects on the ultrastructure of mitochondria by transmission electron microscopy (TEM). Mitochondria of wild type parasites treated with vehicle showed a typical dense matrix with multiple clearly defined cristae ( Fig. 6A ). Treatment of wild type parasites with 8 µM ART for 24 hr resulted in expansion of the matrix, loss of density, and a reduced number of cristae (Fig. 6B ).
The mitochondrial ultrastructure of the ART100 resistant population grown in presence of 100µM ART presented further reduction in matrix density with only few visible cristae ( Fig. 6C ). Removal of the drug from the ART100 population for 24 hr led to partial increase in matrix density and restoration in cristae numbers ( Fig. 6D ).
Discussion
We took advantage of flexible in vitro culture systems and genetic tools available in T. gondii to evolve lines that were resistant to growth-inhibiting effects of ART in order to define potential mechanisms of action. In parallel, we determined the background mutation rate of clones generated after long-term passage in the absence of ART selection. Passage in ART led to enhanced resistance at the population level and whole genome sequencing in the ART-resistant lines identified several nonsynonymous SNPs in the coding sequences of a serine protease homologous to DegP and a serine/threonine kinase named Ark1. We engineered these point mutations into a wild type background using CRISPR/Cas9 and confirmed that they confer a competitive advantage in the presence of ART, although they did not alter the EC 50 value for growth inhibition. Among the ART-resistant lines, we also observed upregulation of heme-containing cytochromes encoded in the mitochondrial genome, consistent with previous studies suggesting a mitochondrial target for ART. Collectively our studies define new mechanisms of mutation that result in ART resistance, including point mutations in specific genes that have not been seen previously, and alterations in mitochondrial function.
Analysis of the frequency of mutations in clones of T. gondii that were grown under standard laboratory conditions led to several surprising findings. First, the rate of apparent mutation in T. gondii was relatively low at ~ 5.8 x10 -11 / mutations / bp / generation. This rate is ~ 30 fold lower than that estimated for P. falciparum (1.7 x10 -9 ) (58), but somewhat closer to rates described in Baker's yeast (3.3 x10 -10 ) (59), or S. pombe (2.0 x10 -10 ) (60). Second, we observed a high level of nonsynonymous (dN) relative to synonymous (dS) mutations in coding regions. In the absence of selection, this ratio is expected to be ~ 1, indicating that strong selection was operating under standard growth conditions. As many nonsynonymous mutations have seemingly been lost from the clones, the true mutation rate is likely to be higher. Previous studies examining SNPs between different lineages of the RH strain that were passaged for an unknown number of doublings in different laboratories also reported elevated dN/dS ratios that ranged from 2 -10 (61). Studies conducted on the model organism E. coli have shown that strong selective pressures exist even under homogeneous conditions and that mutations fluctuate widely over time in frequency but often reach fixation (62). Such mutations also show strong dN/dS skewing and often contribute to fitness advantages (62). In the present study, we did not evaluate the fitness of the mutations that reached fixation in non-selected lines, although the high dN/dS ratio is more consistent with improved growth characteristics rather than potential bottlenecks during passage. Our passaging procedures are highly similar to what most laboratories use for maintenance of T. gondii cultures in vitro, suggesting this could be a widespread phenomenon.
Following culturing at elevated levels of ART, we obtained two parallel populations with increased resistance to ART as evidenced by shifted EC 50 values in an in vitro growth assay. Whole genome sequencing of these lines revealed a number of mutations in each lineage, but two genes stood out as having a high frequency of SNPs in the population and clones from both lines. Since changes in these two genes were most clearly associated with increased resistance, we chose to examine them further.
We reintroduced the point mutations seen in the resistant lines, either alone or in combination, into wild type background using CRISPR/Cas9 to edit the genome. Somewhat surprisingly, introduction of these point mutations did not shift the EC 50 to a similar extent as seen in the original uncloned populations.
Hence, the presence of these mutations alone appears to confer tolerance, but not outright resistance to ART. Although the observed mutations do not correspond to those previously identified in P.
falciparum, the phenotype is reminiscent of the phenotype seen in the RSA where "resistant" lines show improved survival but do not exhibit a shift in the EC 50 (29). The reasons for the difference in EC 50 shift between the engineered clones and the original lines are unclear but might relate to additional background mutations in each of the evolved lineages, or due to alterations in the mitochondrial genome, as discussed below. Regardless, the point mutations did enhance fitness in a competition assay with wild type parasites grown in the presence of ART. Each of the single and double mutants outgrew the wild type cells within the first several passages, despite a lag in the initial expansion. This enhanced fitness was not due to improved growth overall as the DegP mutants showed a growth disadvantage, while the Ark1 mutants were equal to wild type in the absence of ART. Interestingly, the Ark1 mutants rescued the partial growth defect of the DegP mutants in the absence of ART. However, this was not the sole reason for expansion of this allele as the single Ark1 mutations also conferred a competitive advantage vs. wildtype parasites in the presence of ART.
The exact mechanisms by which point mutations in these genes confer enhanced tolerance to ART in T. gondii are unclear but neither of these two genes have been implicated in previous studies on ART resistance in other systems. The mutations seen in T. gondii Ark1 occur in the hinge region of the kinase, a critical spot for ATP binding, suggesting they might affect catalytic activity. The substrates of Ark1 are presently unknown and its role in the biology of the parasite has not previously been explored, although it has a fitness score in a genome-wide CRISPR screen that would suggest it is essential (-3.77) (63). Similarly, the functional consequences of the DegP mutations in conferring tolerance to ART in T. gondii are unclear from the present studies. DegP is a member of the High Temperature Requirement A family (HtrA) and is a periplasmic protease in E. coli (64). In bacteria, DegP is involved in protective stress responses to aid survival at high temperatures (64), a phenotype also reported in yeast (65). Htr orthologs in eukaryotes are typically found in the mitochondria where they function in quality control (66). Given the role of DegP in stress responses, it may play a similar role to K13 in ART resistance in malaria, where mutations in K13 propeller domains have been linked to altered stress responses (32). By analogy, the mutations in the PDZ domains seen in ART resistant T. gondii may affect chaperone activity and/or interaction with its substrates and in the process relieve stress induced by treatment with ART.
Consistent with previous studies in yeast (43) and tumor cells (45, 46) , our findings support the mitochondrion as a target of artemisinin. We observed both a decrease in membrane potential and altered morphology in wild type parasites treated with ART and a stable decrease in membrane potential and altered morphology in resistant populations, suggesting these changes are a long-term adaptation to the presence of drug. Initial studies in yeast suggested that the electron transport chain (ETC) was responsible for activation of the endoperoxide moiety in artemisinins (27, 43) , a functional group that is important for its toxic activity. However, mammalian cell petite mutants, which lack a functional ETC, show no deficiency in formation of cytotoxic radicals and instead chemical modulators support a role for heme in activating the endoperoxide group (46). Nonetheless, such ETC-deficient mammalian cells are more resistant to artemisinins, supporting a role for this pathway through generation of reactive oxygen species and induction of apoptosis (46). The ART100 population of T.
gondii mutants studied here demonstrated reduced ETC activity in both the presence and absence of drug, a feature that would be expected to contribute to enhanced resistance. This suggests that the amplification of the mitochondrial genome and concomitant enhanced transcription of several subunits encoded there creates an imbalance in the components of the ETC, thus impairing its function. Future studies are required to resolve the roles of heme vs. the ETC in activating ART in T. gondii, as well as identifying the targets and pathways that result in cytotoxicity.
Our findings provide support for several previously suggested mechanisms of ART resistance and also make several new predictions about the frequency and consequences of mutation in T. gondii.
First, we identify new point mutants that can confer enhanced survival in the presence of ART without shifting the EC 50 in a classical resistance phenotype. Although the target genes differ, this finding mirrors what is seen in P. falciparum where K13 mutations are associated with enhanced survival in the presence of drug. Second, similar to P. falciparum, the mechanisms of resistance to ART in T. gondii appear to be multigenic and may have a link to altered stress responses. Third, ART may inhibit mitochondrial function in T. gondii and alterations in targets there may thus lead to resistance, as previously suggested by studies done in yeast and tumor cells. Fourth, although the low intrinsic mutation rate in T. gondii may limit the potential for drug resistance to arise in the clinic, our finding that mutational drift occurs readily in the absence of purposefully applied selection predicts that mutations that may alter phenotypes are likely to accumulate during normal laboratory passage. Collectively, these processes may also drive evolution and affect the occurrence of drug resistance and other biological traits in vivo.
Materials and Methods
Reagents and antibodies. μ g/mL gentamicin (Thermo Fisher Scientific), 10 mM glutamine (Thermo Fisher Scientific)]. HFF cells were grown as confluent monolayers in T25 2 flasks and inoculated with ~2x10 6 parasites that expanded by ~ 10 fold over 2-3 days of culture. Following natural egress, the cultures were split by 1:10 or 1:20 dilution of the growing culture to a fresh uninfected HFF monolayer growing in a T25 2 flask. In order to harvest parasites for the assays described below, parasites were allowed to egress naturally and tachyzoites were purified by filtration through 3 micron polycarbonate filters (Whatman) in Hank's balanced salt solution supplemented with 0.1 mM EGTA and 10 mm HEPES, pH 7.4, followed by centrifugation at 400 g. Clones were isolated by limited dilution and outgrowth on monolayers of HFF cells grown in 96 well plates. All strains and host cell lines were determined to be mycoplasma negative using the e-Myco plus kit (Intron Biotechnology).
Parasite Transfection. Following natural egress, freshly harvested parasites were transfected with plasmids, using protocols previously described (69) Plasmid Construction and Genome Editing. All CRISPR/Cas9 plasmids used in this study were derived from the single guide RNA (sgRNA) plasmid pSAG1:CAS9-GFP, U6:sgUPRT (70) by Q5 sitedirected mutagenesis (New England Biolabs) to alter the 20 nt single guide RNA (sgRNA) sequence, as described previously (71). Primers for plasmids are listed in SI Appendix Table S5 . Separate sgRNA plasmids were made for editing mutations in DegP (i.e. pSAG1:CAS9-GFP, U6:sgDegP G806E ; pSAG1:CAS9-GFP, U6:sgDegP [G821Q] ;) and Ark1 (i.e. pSAG1:CAS9-GFP, U6:sgArk1). Generation of point mutant parasites in endogenous genes. To introduce point mutations into endogenous genes, we used a markerless genome editing strategy. RHluc parasites were cotransfected with a dual-functional Cas9-green fluorescent protein (GFP) / sgRNA plasmid designed to cut within the vicinity of the codon of interest and a Cas9-shielded homology donor amplicon. This amplicon provides a repair template (~500 bp) containing the point mutation of interest along with a silent mutation that would either introduce a novel restriction site or eliminate an existing one (SI Appendix Table S6 ). Following transfection, parasites transiently expressing Cas9-GFP were isolated by FACS, as described above. Single clones were isolated from the FACS-sorted population by limiting dilution on HFF monolayers in 96 well plates. Following isolation of clones, a 500 bp fragment surrounding the mutant allele was amplified by PCR using primers described in SI Appendix Table S4 followed by diagnostic restriction enzyme digestion that would distinguish the wild type and edited alleles. Clones that were positive by restriction enzyme digestion were expanded and further confirmed sequenced by the Sanger. After 30 min of incubation at 37°C, cells were washed and then fixed. Parasites were labeled with rabbit 1:2,000 anti-TgTom-40 as primary antibody followed by 1:2,000 anti-rabbit IgG-Alexa 488 as secondary antibody. Mini protease inhibitor cocktail (Roche). Cell supernatants were collected after centrifugation at 6,000 × g for 10 min at room temperature (RT) to avoid cell debris. Total protein was measured in each sample using the bicinchoninic acid (BCA) protein assay kit (Pierce, Thermo Fisher Scientific). Samples were boiled at 95°C for 15 min in Laemmli buffer containing 100 mM dithiothreitol (DTT). Samples were separated using SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked in a 1:1 mixture of Odyssey blocking buffer (OBB; Li-Cor Biosciences) and PBS overnight at 4°C. The membrane was incubated with rabbit polyclonal anti-TgTom40 and mouse anti-GRA2 at 1:2,000 and 1:1,000 respectively for 2 hr at RT in a 1:1 mixture of Odyssey blocking buffer and PBS with 0.1% Tween 20 (PBS-Tween). The blot was washed three times for 5 min each with PBS-Tween and incubated with anti-rabbit IgG IR800 and anti-mouse IgG IR680 at 1:15,000 for 2 hr at RT in a 1:1 mixture of Odyssey blocking buffer and PBS-Tween. The blot was washed three times for 5 min each with PBS-Tween followed by infrared imaging on a Li-Cor Odyssey imaging system. Then, the fragments were modified to contain an "A" base to 3' end with Klenow (3′→ 5′ exo-), and ligated to Illumina's sequencing adapters with T4 DNA ligase. Half of the ligated fragments underwent amplification for 8 cycles incorporating a unique indexing sequence tag with VeraSeq DNA Polymerase.
Generation of Firefly
TMRE Mitochondrial Membrane
All enzymes were purchased from QIAGEN. The resulting libraries were normalized and sequenced using the Illumina HiSeq-3000 as paired end reads extending 150 bases from both ends of the fragments. Illumina's bcl2fastq utility was used to demultiplex the samples.
SNP analysis.
Reads were aligned to the T. gondii ME49 reference genome (ToxoDB release 41) using BWA-mem (75) and further processed using Picard Tools (http://broadinstitute.github.io/picard/).
SNVs and INDELs were called using GATK HaplotypeCaller, then filtered based on GATK recommendations (76). Briefly, SNV calls were retained if they met the following criteria:
ReadPosRankSum >8.0 or <-8.0, QUAL<500, Quality by Depth (QD) <2.0, Mapping Quality Rank Sum <-12.5, and filtered depth (DP) <7. Indels were retained if they met the following criteria:
ReadPosRankSum <-20, QUAL<500, QD<2, and DP<7. Mutations were annotated with a custom SnpEff (77) database built from a GFF file. Variants were further filtered by removing mutations that were present in both the parent strain and evolved strains, such that mutations were only retained if they arose during the course of long-term culturing for neutral mutation rate experiments or the drug selection process for artemisinin-pressured lines. Manual inspection of the resulting SNPs was used to remove polymorphisms where the read depth for a majority of clones was below the cutoffs stated above, since correct assignment of genotypes was ambiguous in many of these cases.
Statistical analysis of mutation rate by whole genome sequencing. The mutation rate was calculated based on the number of SNPs identified in each of the subclones from the unselected 5D
and 12B lines sampled at 182 or 365 days. For these calculations, we assumed that the growth rate and mutation rate are constant across the experiment. We also assumed that the observed mutations (50)). Identical mutation that were observed in more than one clone were only counted once (as designated in Datasets S1, S2). We calculated the average mutation rate for the 365 day clones from the individual clones for the two separate lines.
We also estimated the mutation rate by treating the whole genome sequencing results for all unselected clones from the 56D and 12B series as a fluctuation analysis, scoring the number of SNPs (mutations) for each of the clones over 728 doublings equal to 182 days of culture (for clones sampled at 365 days the number of SNPs was halved to allow direct comparison), under the assumption that the mutants have equal fitness to the wild type. Mutation rates were calculated using bz-rates (http://www.lcqb.upmc.fr/bzrates ) (78) based on equations that have been described previously (79).
Copy number variation (CNV) analysis.
Estimation of CNV was calculated as previously described (47 end option (80) and SAM files were converted to BAM format using samtools version 1.9 (81). Average read depth and standard deviation for each gene in the T. gondii genome was obtained using samtools mpileup option across the genomic start:stop positions for each annotated CDS. The genomic 1X mean read depth for each sample was calculated as the average read depth across all base pairs within genomic start:stop positions for CDSs with average read depth between the first and third quartiles off all genes, as determined using the quartile function in R. Copy depth is either the gene average or bp level read depth normalized to the 1X genomic mean for that sample. For both analyses described below, CNV for control genes TGME49_308090 (ROP5 -6-7 copies), TGME49_212740 (AAH2 -2 copies), and TGME49_271580 (TgFAMD -2 copies) match previous estimates of CNVs in the type I RH strain (47) 
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